Repertoire Immune Medicines, a biotechnology company developing programmable T cell targeted immune medicines, has entered a multi-year strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for autoimmune disease by resetting the immune system.   Repertoire will receive $65 million upfront, and up to $1.8 billion for achieving development, regulatory ...